147770-08-9 Usage
Description
(R)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid ethyl ester, also known as (R)-Repaglinide Ethyl Ester, is a chemical compound that is identified as an impurity in Repaglinide (R144500). Repaglinide is a non-sulfonylurea oral hypoglycemic agent, which is utilized for the treatment of diabetes mellitus. (R)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid ethyl ester is characterized by its complex structure, which includes an ethyl ester group, a benzoic acid core, and various substituents that contribute to its properties and potential applications.
Uses
Used in Pharmaceutical Industry:
(R)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid ethyl ester is used as an impurity in the production of Repaglinide (R144500) for the treatment of diabetes mellitus. As an impurity, it is essential to monitor and control its presence in the final product to ensure the safety, efficacy, and quality of the antidiabetic medication.
In the pharmaceutical industry, the control and management of impurities, such as (R)-Repaglinide Ethyl Ester, are crucial for maintaining the overall quality and safety of medications. Impurities can potentially affect the pharmacological activity, stability, and safety profile of the drug. Therefore, the identification, quantification, and control of impurities like (R)-Repaglinide Ethyl Ester are vital steps in the drug development and manufacturing process.
Additionally, understanding the properties and potential applications of impurities can provide valuable insights into the development of new drugs or the improvement of existing ones. In the case of (R)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid ethyl ester, further research may reveal additional uses or applications in the pharmaceutical industry, potentially leading to the development of new therapeutic agents or drug delivery systems.
Check Digit Verification of cas no
The CAS Registry Mumber 147770-08-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,7,7 and 0 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 147770-08:
(8*1)+(7*4)+(6*7)+(5*7)+(4*7)+(3*0)+(2*0)+(1*8)=149
149 % 10 = 9
So 147770-08-9 is a valid CAS Registry Number.
147770-08-9Relevant articles and documents
Repaglinide and related hypoglycemic benzoic acid derivatives
Grell, Wolfgang,Hurnaus, Rudolf
, p. 5219 - 5246 (2007/10/03)
The structure-activity relationships in two series of hypoglycemic benzoic acid derivatives (5, 6) were investigated. Series 5 resulted from meglitinide (3) when the 2-methoxy was replaced by an alkyleneimino residue. Maximum activity was observed with the cis-3,5-dimethylpiperidino (5h) and the octamethyleneimino (5l) residues. Series 6 resulted from the meglitinide analogon 4 bearing an inversed amido function when the 2-methoxy, the 5- fluoro, and the α-methyl residue were replaced by a 2-piperidino, a 5- hydrogen, and a larger α-alkyl residue, respectively. An alkoxy residue ortho to the carboxy group further increased activity and duration of action in the rat. The most active racemic compound, 6al (R4 = isobutyl; R = ethoxy), turned out to be 12 times more active than the sulfonylurea (SU) glibenclamide (1). Activity was found to reside predominantly in the (S)- enantiomers. Compared with the SUs 1 and 2 (glimepiride), the most active enantiomer, (S)-6al (AG-EE 623 ZW; repaglinide; ED50 = 10 μg/kg po), is 25 and 18 times more active. Repaglinide turned out to be a useful therapeutic for type 2 diabetic patients; approval was granted recently by the FDA and the EMEA. From investigations on the pharmacophoric groups in compounds of type 5 and 6, it was concluded that in addition to the two already known - the acidic group (COOH; S02NH) and the amidic spacer (CONH; NHCO) - the ortho residue R1 (alkyleneimino; alkoxy; oxo) must be regarded as a third one. A general pharmacophore model suitable for hypoglycemic benzoic acid derivatives, SUs, and sulfonamides is proposed (Figure 6). Furthermore, from superpositions of low-energy conformations (LECs) of 1, 2, and (S)-6al, it was concluded that a common binding conformation (LEC II; Figure 10B) may exist and that differences in binding to the SU receptor and in the mechanism of insulin release between repaglinide and the two SUs may be due to specific hydrophobic differences.
